Publications by authors named "Landon Chan"

Claim this Profile
N
New targets and new drugs for hepatobiliary cancers.
Stephen L Chan, Angela Lamarca, Chiun Hsu, Victor Moreno, Landon L Chan

J Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment for hepatocellular carcinoma after immunotherapy.
Landon L Chan, Tsz Tung Kwong, Johnny C W Yau, Stephen L Chan

Ann Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era.
Landon L Chan, Anthony W H Chan, Terry C F Yip, Grace L H Wong, Alvin K H Ngai, Stephen L Chan

J Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.
Johnny C W Yau, Landon L Chan, Stephen L Chan

Hepat Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.
Allen C C Chen, Florence S T Mok, Wesley K Y Wong, Benjamin H W Lam, David Johnson, Landon L Chan

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What's next after the 2025 BCLC update?
Landon L Chan, Stephen L Chan

J Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications of Upregulated Gene Expression in Hepatocellular Carcinoma.
Leung Li, Nelson L S Tang, Stephen L Chan, David Ryan Johnson, Frankie Mo, Landon Long Chan

Diseases· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D.
Tiantian Qin, Yi Ching Esther Wan, Shiman Hu, Jiaohua Chen, Xiaoxuan Zhu, Landon Long Chan, Kui Ming Chan

Cell Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions-Authors' Reply.
Landon Long Chan, Dorothy Cheuk-Yan Yiu, Terry Cheuk-Fung Yip, Stephen Lam Chan

Aliment Pharmacol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.
Dorothy Cheuk-Yan Yiu, Jimmy Che-To Lai, Landon Long Chan, Grace Lai-Hung Wong, Mandy Sze-Man Lai, Henry Lik-Yuen Chan, Stephen Lam Chan

Aliment Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
Stephen Lam Chan, Hui-Chuan Sun, Yang Xu, Hongmei Zeng, Hashem B El-Serag, Landon L Chan

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnostics.
Mary-Jane L Ma, Woody Z Zhang, Peiyong Jiang, Lu Ji, Dongyan Xiong, Landon L Chan, W T Charlotte Chan, Stephen L Chan, K C Allen Chan

Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression.
Wesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, Olivia H Chen, Herbert H F Loong, Landon L Chan

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries.
Choong-Kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, Landon Long Chan, Stephen Lam Chan

Liver Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future perspectives on immunotherapy for hepatocellular carcinoma.
Landon L Chan, Stephen L Chan

Ther Adv Med Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic therapy for child-pugh B patients with hepatocellular carcinoma.
Kevin Mok, Olivia Chen, Johnny Yau, Landon L Chan, Stephen L Chan

Expert Opin Emerg Drugs· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk.
Olivia H Chen, Wesley K Y Wong, Kevin K S Mok, Landon L Chan, Candy Tang

Clin Lung Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer.
Tsz Tung Kwong, Hao Hao Deng, Chi-Hang Wong, Anthony W H Chan, Landon Long Chan, Stephen Chan

Cancer Res Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation immunotherapy: igniting new hope for lung cancer.
Molly S C Li, Andrew L S Chan, Kevin K S Mok, Landon L Chan, Tony S K Mok

Ther Adv Med Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Predictive Algorithm toward Risk-Based Surveillance for Liver Cancer.
Landon L Chan, Vincent W S Wong, Stephen L Chan

NEJM Evid· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
Stephen L Chan, Baek-Yeol Ryoo, Frankie Mo, Landon L Chan, Jaekyung Cheon, Changhoon Yoo

J Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
Jaekyung Cheon, Sanghoon Jung, Jung Sun Kim, Beodeul Kang, Hyeyoung Kim, Landon L Chan, Stephen L Chan, Chan Kim

Liver Int· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
Stephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, Landon L Chan, Wesley K Y Wong, Johan W K Chan

Lung Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma.
Landon L Chan, Kevin Mok, Stephen L Chan

J Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.
Molly S C Li, Kirsty W C Lee, Kevin K S Mok, Herbert H F Loong, K C Lam, Landon L Chan, K P Chan

JTO Clin Res Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis